title: [Antifungal treatment options in the critically ill patient].
abstract: Invasive fungal infections, especially in the critical care setting, have become an excellent target for prophylactic, empiric, and pre-emptive therapy interventions due to their associated high morbidity, mortality rate, increased incidence, and healthcare costs. For these reasons, new studies and laboratory tests have been developed over the last few years in order to formulate an early therapeutic intervention strategy in an attempt to reduce the high mortality rate associated with these infections. In recent years, evidence-based studies have shown the roles that the new antifungal drugs play in the treatment of invasive mycosis in seriously ill and complex patients, although data from critically ill patients are more limited. New antifungal agents have been analyzed in different clinical situations in critical care units, and the increasing number of non-Candida albicans species suggest that the application of early echinocandin therapy in critically ill patients with invasive candidiasis is a good option. Voriconazole should be recommended for invasive aspergillosis as a first line option.
authors.affiliation: Servicio de Medicina Intensiva, Hospital Universitario Dr. Peset, Valencia, España.
authors.forename: Rafael
authors.initials: R
authors.lastname: Zaragoza
authors.forename: Javier
authors.initials: J
authors.lastname: Pemán
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D016638:Critical Illness; D003663:Decision Trees; D006801:Humans; D009181:Mycoses / Q000188:drug therapy*; D017410:Practice Guidelines as Topic
chemical_list: D000935:Antifungal Agents